BioWorld

June 18, 2008

View Archived Issues

Genzyme Seeks Mozobil Nod in Lymphoma, Multiple Myeloma

Cambridge, Mass.-based Genzyme Corp. submitted marketing applications in the U.S and Europe for its lymphoma and multiple myeloma treatment Mozobil (plerixafor), a small-molecule CXCR4 chemokine receptor antagonist. (BioWorld Today) Read More

$30M Fund Would Aid Aussie Academics, Spur Spinouts

Read More

U.S. Biosimilar Debate Crucial to Worldwide Biotech Industry

Read More

India: Moving from Services to Sustainable Innovation

Read More

Elan Rises on Phase II Data in Alzheimer's Disease

Read More

Japanese Partnerships Offer Opportunities, Challenges

Read More

Other News To Note

Read More

Clinic Roundup

Read More

Financings Roundup

Read More